AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of Risankizumab in patients with moderate to severe ulcerative colitis. This real-world study aims to assess ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a clinical study titled ‘A ...

At week 16, 55.9% of the risankizumab group and 5.1% of the apremilast group achieved PASI 90. 75.4% of risankizumab-treated patients vs. 18.4% of apremilast-treated patients achieved sPGA 0/1 by ...

The trial has an estimated study completion date of February 2028. Risankizumab was FDA approved in 2022 for adults with moderate-to-severe CD, as was ustekinumab in 2016.

Risankizumab is an interleukin (IL)-23 p19 inhibitor that was approved for the treatment of adults with moderately to severely active Crohn's disease in June 2022, while ustekinumab is an IL-12/23 ...

Risankizumab, an interleukin-23 (IL-23) inhibitor, is currently marketed under the trade name Skyrizi and is approved for the treatment of active psoriatic arthritis, moderately to severely active ...

The FDA approved risankizumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, in March 2019 for the treatment PsA in adults.

3.3 Risankizumab is a novel treatment with a different mechanism of action to existing treatments. The company proposed it can be used either after conventional treatment (conventional care failure ...

In the risankizumab arm, 84.7% of patients achieved PASI 75 at week 16 vs 18.8% of patients in the apremilast arm (secondary endpoint; P <.001).

Risankizumab is approved in the United States for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a humanized ...

In the risankizumab group, median time to first asthma worsening was 40 days, significantly worse than the 86 days reported for the placebo group (hazard ratio, 1.46; 95% CI, 1.05 – 2.04; P = .03).

Risankizumab appeared to worsen severe asthma symptoms compared with placebo, according to results of a randomized phase 2a study published in The New England Journal of Medicine. Risankizumab ...